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found between 10-year TTO utility and FACT-BR scores (p<0.01), 10-year TTO 
utility and MDASI-BT (Sleep) scores (p=0.039), 5-year TTO utility and FACT-BR 
scores (p<0.01), and 5-year TTO utility and MDASI-BT (Sleep) scores (p=0.039). 
NCF and KPS scores were not significantly associated with TTO utility. The 
analysis of within-patient changes over time indicated significant mean group 
increases in 10-year TTO utility (p=0.021) and NCF (HVLT-R Total Recall) scores 
(p=0.032); however, KPS score significantly decreased (p<0.01). CONCLUSIONS: 
Patients’ quality of life and sleep disturbance symptoms have significant but 
small effects on the patients’ willingness to trade time. The lack of correlation 
between TTO utility and functional status as well as cognitive function suggests 
that patients’ preferences for better health and for quantity of life are primarily 
influenced by the expected length of time until death and not by their current 
health state.  
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OBJECTIVES: To evaluate the quality of life (QoL) among women with cervical 
lesions using the EuroQol EQ-5D instrument to establish utilities of health states 
in mainland China. METHODS: Patients with cervical precursor lesions and 
cancer were recruited from the West China Second Affiliated Hospital between 
May 2010 and January 2011. They were surveyed with the EQ-5D prior to 
treatment, and at 1, 3 and 6 months after treatment. We calculated QoL scores 
through the five-item descriptive system of health states of the EQ-5D and the 
classic UK preference weighting system. RESULTS: A total of 194 women 
completed the questionnaire, including 78 with cervical precursor lesions, 85 
with early cervical cancer (FIGO Stage Ia, Ib and IIa), and 31 with advanced 
cervical cancer (FIGO stage IIb+).  Statistically significant differences were noted 
in QoL scores between different stages of cervical lesions (F=33.94, P<0.001) and 
between different time points (F=23.41, P<0.001). Pairwise comparisons showed 
that there was a consistent decline in the QoL scores in the spectrum of cervical 
lesions at each time point after treatment (all P<0.05). There existed an 
increasing trend in the timeline of treatment among women with cervical 
precursor lesions, though the QoL scores were not statistically different between 
3 and 6 months after treatment (P=0.099). For early cervical cancer, the QoL 
scores declined in the first month of treatment (P=0.057), and increased to a 
higher level than prior to treatment at 6 months (P<0.001). Despite a statistical 
difference between 1 and 6 months after treatment (P=0.016), advanced cervical 
cancer showed a similar secular trend. CONCLUSIONS: Women with early stage 
of cervical lesion have better QoL than those with late stage of disease. The QoL 
improves for cervical precursor lesions as treatment continues, while it declines 
for cervical cancer patients in the immediate time after treatment and increases 
afterwards.  
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OBJECTIVES: Next generation genomic sequencing is a promising transformative 
technology; however, little is known about factors that influence patients’ 
preferences for the return of incidental findings that are likely to be an inevitable 
aspect of genome sequencing. The objective of this study was to identify the 
attributes of incidental findings important to patients and develop a discrete 
choice experiment (DCE) to quantify patient preferences. METHODS: An initial 
set of key attributes and levels was developed from a literature review and in 
consultation with experts. The attributes’ salience and comprehension were 
refined using focus groups (FG) (2 groups, N=12 total) and cognitive interviews 
(CI) (N=6) with patients who received genetic testing for familial colorectal cancer 
or polyposis syndromes. The attributes and levels used in the hypothetical 
choices presented to FG and CI participants were constructed using an 
orthogonal main-effects experimental design. RESULTS: Overall, we observed a 
wide range of preferences for genomic sequencing information; however, 
patients tended to focus on the importance of several consistent attributes in 
describing their preferences. The final DCE instrument incorporates the 
following attributes and levels: lifetime risk of developing the disease (5%, 40%, 
70%); disease treatability (medical intervention available, lifestyle intervention 
available, or none); disease severity (mild, moderate, severe); carrier status (yes, 
no); drug response likelihood (high, moderate, none), and out-of-pocket test cost 
($250, $425, $1000, $1900). CONCLUSIONS: Individual patient preferences for 
incidental genomic findings are likely influenced by a complex set of diverse 
attributes. This study identified an initial set of important factors, though further 
research is needed to explore preferences in different settings and to develop 
effective ways of helping patients and providers understand and address these 
preferences in the return of incidental findings. Measuring preferences using 
DCE instruments may facilitate patient-provider communication by quantifying 
patients’ personal utility for particular attributes of incidental findings.  
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OBJECTIVES: To identify possible changes in patient-reported outcomes (PRO), 
including health-related quality of life (HRQoL), of multiple myeloma (MM) 
patients undergoing treatment in the USA. PRO of those meeting CRAB criteria 
(hyperCalcemia, Renal insufficiency, Anemia, Bone lesions) for 
active/symptomatic MM was assessed at baseline and 1 year post-baseline. 
METHODS: Data were collected in Connect® MM, an ongoing prospective US 
disease registry of MM patients. Clinicians reported patient demographics and 
clinical characteristics. PRO were recorded at baseline, within 2 months of 
diagnosis, and 1 year post-baseline by completing Brief Pain Inventory (BPI), EQ-
5D, and Functional Assessment of Cancer Therapy (FACT)-MM questionnaires. 
Mean (± standard deviation) BPI, EQ-5D, and FACT-MM change scores were 
analyzed. Statistical significance was assessed. RESULTS: Overall, 636 patients 
(from 189 centers) meeting CRAB criteria provided data at baseline and 1 year 
post-baseline. The majority of patients were male (58%), white (84%), with a 
mean age of 66 (±11) years. Patients were seen in academic (17%), community 
(81%), or government (2%) clinical centers. Evaluable International Staging 
System stages were: I (29% of patients); II (35%); and III (35%). Average pain 
improved over 1 year (P < 0.0005). HRQoL/functional ability improved in 4 of 5 
FACT domains (except social/family; all others P < 0.0001), and in 4 of 5 EQ-5D 
domains (except pain/discomfort; all other P values ranged from 0.0142 to  
< 0.0001). Overall HRQoL, as shown by FACT-MM and FACT-General total scores, 
also improved (both P< 0.0001). Overall HRQoL improved in males and females, 
and in younger age groups (<65 and 65–74 years), but not in those ≥ 75 years. 
CONCLUSIONS: Connect® MM findings indicate that most PRO improved 
between baseline and 1 year post-baseline. Data will be examined to identify 
which disease- and treatment-related factors are associated with HRQoL 
improvement in this MM population.  
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OBJECTIVES: Existing measures of opioid-induced constipation (OIC) symptoms 
have not been developed in accordance with FDA’s 2009 Guidance for Patient-
Reported Outcome (PRO) Measures. The OIC Rating Scale (ORS) was developed 
based on literature and comprehensive qualitative research. This study aimed to: 
1) validate a conceptual framework of two domains; 2) determine the optimal 
scoring system; 3) examine item- and scale-level psychometrics; and 4) establish 
domain responder definitions (RD). METHODS: ORS was administered to 215 US 
adults with OIC in a Phase II study. Confirmatory factor analysis (CFA) was used 
to test the fit of the previously developed conceptual framework. The evaluation 
analyzed data from the 2-week baseline period and the 5-week treatment period. 
Item response theory (IRT) was used to determine an optimal scoring approach, 
followed by classical psychometrics including item- and scale-level reliability, 
and convergent validity. Distribution- and anchor-based approaches were used 
to determine the RD for each domain based on week 5 change from baseline. 
RESULTS: Based on descriptive statistics, item-level correlations, and CFA results 
(confirmatory fit index/non-normed fit index >0.96, standardized root mean 
residual <0.04), a two-domain structure of the ORS was validated and carried 
forward in tests of reliability (αs > 0.85, test-retest ICCs >0.60) and validity 
analyses (convergent rs 0.37-0.55), and to establish score interpretation. IRT 
results provided no compelling evidence requiring special item weights rather 
than a simple raw sum-score per domain. The two-item bowel movement 
symptom (BMS) domain RD = 2 and six-item gastrointestinal-related symptom 
(GRS) domain RD = 4. CONCLUSIONS: The ORS instrument demonstrated strong 
psychometric characteristics using analyses following the current FDA guidance 
for PRO measures. The two domains explained the correlations among the bowel 
movement and gastrointestinal-related symptoms in OIC. These results support 
further use of this instrument in studies of potential treatments for OIC.  
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OBJECTIVES: Metastatic castration-resistant prostate cancer (mCRPC) continues 
to be an aggressive and life-threatening cancer. With approved drugs providing 
only modest survival benefits, there is an increasing interest on improving 
symptoms and health-related quality of life (HRQoL). The aim of this review is to 
understand the impact of mCRPC treatments on HRQoL. METHODS: The search 
was conducted on PubMed®. Additional articles were found from cross-
referencing, and on ASCO and ESMO websites. A multi-step approach ensured 
that a wide range of mCRPC studies were reviewed. The search was limited to 
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English, human-only abstracts from January 1, 1992 to December 31. RESULTS: 
Quality of life evaluations for the following compounds were included in the 
review: abiraterone, cabazitaxel, docetaxel, enzalutamide, mitoxantrone, 
radium-223, samarium-153, and strontium-89. Significantly greater quality of life 
response was observed in the enzalutamide population compared to placebo 
(43% vs. 18%) while docetaxel showed significant difference in a head-to-head 
comparison with mitoxantrone on pain response (31-35% vs. 22%) as measured 
by the McGill questionnaire. Cabazitaxel did not show a significant difference in 
pain response compared to mitoxantrone. Abiraterone showed significant 
difference in multiple outcomes: pain palliation (44% vs. 27%) as measured by 
BPI-SF; reduction in fatigue intensity (58% vs. 40%) as measured by BFI; and time 
to HRQoL degradation (12.7 vs. 8.3 months) as measured by FACT-P. Abiraterone 
is the only agent reviewed to be effective in survival, pain palliation and 
progression and HRQoL. Additionally, abiraterone uniquely measured and 
showed benefit in fatigue. No patient-reported outcomes were pursued for 
sipuleucel-T. EORTC QLQ-C30 and FACT-P were the most common HRQoL 
instruments used. CONCLUSIONS: Studies in mCRPC typically include endpoints 
for pain palliation and quality of life improvement. Additionally, novel therapies 
are focusing on pain associated with bone metastases. There is no standard 
HRQoL or pain instrument being consistently used across prostate cancer trials.  
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OBJECTIVES: 1) To identify products indicated for treatment of non-small-cell 
lung carcinoma (NSCLC) approved with a PRO labeling claim in Europe and the 
US; and (2) to list the differences found in Europe versus the US in terms of 
products and labeling. METHODS: The search was performed on the Food and 
Drug Administration (FDA) and European Medicines Agency (EMA) approved 
medicinal product labels and on the FDA medical reviews and EMA scientific 
discussions. RESULTS: A total of 15 products (generics excluded) were identified, 
six at the EMA and nine at the FDA. The six products approved by the EMA were 
also approved by the FDA. Four products with a PRO claim were identified in 
Europe (i.e., docetaxel, erlotinib, gefitinib and paclitaxel), and two in the US (i.e., 
paclitaxel and gemcitabine). Most of the PROs identified in the claims were 
quality of life and symptoms. For four products (i.e., docetaxel, erlotinib, gefitinib 
and paclitaxel), the EMA and FDA showed disagreement in terms of PRO labeling. 
The EMA gave a PRO claim (quality of life and symptom) to three products, but 
not the FDA; for paclitaxel, the FDA did not include quality of life in the label. 
Except for gefitinib, the reviews of both agencies were conducted on the same 
clinical studies. The analysis of the medical reviews and scientific discussions 
showed that FDA did not include the PROs in the label because of concerns about 
the quality of the study design, of the analyses, or the questionnaires’ content 
validity. CONCLUSIONS: Our review showed that the patients’ perspective in the 
treatment of non-small-cell lung carcinoma is important for the EMA and FDA. 
However, differences exist in the evaluation of PRO data for inclusion in the 
label. Our analysis suggests a higher receptivity of EMA to quality of life as a 
global concept.  
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OBJECTIVES: Patient reported outcomes (PRO) are becoming useful tools for 
collecting and generating evidence for new medical products to show 
improvements in health-related quality of life (HRQoL). Chronic myeloid 
leukemia (CML) is now a chronic disease in which HRQoL is becoming important. 
The objective of this study was to review, analyze, and understand trends in the 
PRO instruments used in patients with CML. METHODS: A systematic literature 
search for CML randomized controlled trials (RCTs) with PROs endpoints was 
undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, and 
Cochrane. Data was collected for the study size, interventions, year, PRO 
instrument, and results for PROs. Analysis was conducted to identify trends in 
commonly used PRO instruments and results were categorized as positive, 
neutral, or negative. RESULTS: Eight RCTs with a total of 3342 patients were 
identified. In these studies, there were eight different PROs instruments 
identified: FACT-Leu, SF-36, FSI, PSQI, MSAS-SF, FACT-BRM, EQ-5D, and MDASI-
CML. The most commonly used instruments were FACT-Leu (used in 1336 
patients) and FACT-BRM (used in 1199 patients). Five studies reported positive 
results with improvement in quality of life (QoL) symptoms versus comparator 
treatments. Two studies reported results highlighting significant deterioration in 
QoL versus patients with no cancer. One study reported QoL in various types of 
CML and showed significant deterioration in patients with chronic phase CML 
versus those with acute and blast phase CML. Studies also identified two QoL 
domains, depression and fatigue, which matter most for patients with CML. 
CONCLUSIONS: Patients with CML have significant deterioration in their QoL. 
PRO instruments such as FACT-Leu and FACT-BRM can aid in generating 
evidence to show which therapies improve patient QoL.  
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OBJECTIVES: With increasing interest in patient-reported outcomes and 
technological advances, the mode of data collection has shifted focus from 
paper-based self-administered surveys to computerized electronic device-
assisted surveys. The study purpose was to examine differences in quality of 
data collected, via paper-based vs. electronic web-based surveys delivered via an 
iPod among cancer patients in West Virginia. METHODS: Convenience sampling 
was used to recruit participants from the Mary Babb Randolph Cancer Center 
(MBRCC) in Morgantown, WV. Eligible respondents were: adults 18 years and 
above; receiving treatment or scheduled for follow-up at MBRCC following cancer 
diagnosis; fluent in English; and consented to participate. Respondents were 
screened and no information was retained from those who refused or were 
ineligible. The study was approved by West Virginia University Institutional 
Review Board. Electronic web-based data were saved to a secure server in SPSS 
software format. Data from paper-based surveys were collected and manually 
entered into a SPSS database. RESULTS: There were 87 electronic web-based 
survey responses; however, due to technical issues, only 67 had complete data. 
This missing pattern occurred in the first 20 surveys, although electronic survey 
design did not allow skipping questions. Responses for 101 paper-based surveys 
were recorded with no unique missing pattern identified; however, 12 
respondents skipped the income question, resulting in missing demographic 
data. Web-based surveys handled skip patterns better, with more accurate data 
collection; however, respondents reported difficulties in iPod data collection, 
such as small screen size and difficulty using the slide bar. CONCLUSIONS: 
Despite widespread interest and increasing use, electronic handheld data 
collection devices should be used with caution. Technical problems with internet 
connectivity and missing data submission to web-based servers may be 
limitations. Electronic data collection may also be less appropriate for specific 
subpopulations, such as the elderly, or those unfamiliar with computer 
technology.  
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OBJECTIVES: Patient Reported Outcomes (PROs) play an important role in 
evaluating patient quality of life and comparative efficacy of various treatments. 
Another potential use of PROs is for chronic disease management, which can 
provide useful data to physicians and patients. We developed a novel web and 
phone based PROs tool for management of prostate cancer disease. METHODS: 
PRO methods for prostate cancer were reviewed by analyzing published clinical 
studies. KOLs and patient advocacy groups were interviewed to obtain their 
input for design of PRO disease management tool. Recent technologies for 
developing such tools were reviewed by analyzing available electronic PRO tools. 
PROCDIM design was developed based on secondary research and primary 
interviews. RESULTS: PROCDIM was designed to capture patient reported 
outcomes data such as Quality of Life (using five attributes), adverse events (six 
commonly reported AEs), medications and OTC drugs history, PSA antigen score, 
past surgery and radiation therapy, and record of physician appointments. 
Patients could enter data into PROCDIM using web or phone (iphone or andriod) 
based systems. Data from PROCDIM could be emailed by the patient to the 
provider or could be downloaded by tethering a phone to a computer. Pilot data 
was captured by testing PROCDIM with physicians and patient advocacy groups. 
Based on interviews, PROCDIM was rated superior and highly user friendly 
compared to current chronic disease management tools. Patient outcomes data 
would be collected from a planned IRB approved study. CONCLUSIONS: 
PROCDIM is a valuable tool to capture several patients reported outcomes and 
data for chronic disease management. Such tools could be used for collecting 
data for disease management, clinical trial, and observational studies for various 
chronic diseases.  
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OBJECTIVES: Gene expression profiling (GEP) of tumours informs baseline risk 
prediction, potentially affecting decisions about adjuvant chemotherapy for 
women with early breast cancer (BrCa), of whom only 15% will experience a 
recurrence. Limited evidence exists on the clinical utility of GEP in chemotherapy 
treatment decisions. We aimed to measure the value of GEP testing information 
in chemotherapy treatment decisions based on risk-benefit tradeoffs from a 
stated preferences study. METHODS: Based on literature review, focus groups 
and interviews with BrCa patients and medical oncologists, we developed a 
discrete choice experiment survey. For our pilot, we surveyed BrCa patients 
(n=27), women from the general public (n=55), and medical oncologists (MOs; 
n=3) across Canada. The DCE included 12 choice tasks with 5 attributes and 3 
scenario profiles considering orthogonality, D-efficiency and level balance. 
Preferences were analyzed using conditional logit and hierarchical Bayes and 
evaluated for goodness-of-fit. RESULTS: Most (>80%) respondents know 
someone who had chemotherapy for cancer. However, few respondents (<10%) 
know someone who had GEP testing. Across the three groups, the most 
important attributes in chemotherapy treatment decisions were (in order): GEP 
